ストックスクリーナーアプリを入手
41.95
1.55%
-0.66
アフターアワーズ：
41.95
前日終値:
$42.61
開ける：
$42.23
24時間の取引高:
849.36K
Relative Volume:
0.84
時価総額：
$3.29B
収益：
$866.00K
当期純損益:
$-283.65M
株価収益率:
-9.8313
EPS:
-4.267
ネットキャッシュフロー:
$-226.25M
1週間 パフォーマンス:
+0.58%
1か月 パフォーマンス:
+9.90%
6か月 パフォーマンス:
+82.39%
1年 パフォーマンス:
+68.20%
1日の値動き範囲:
$40.88
$42.34
1週間の範囲:
$40.88
$45.14
52週間の値動き範囲:
$20.37
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Compare CLDX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
41.95 | 3.52B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-20 | アップグレード | Barclays | Underweight → Overweight |
| 2026-03-23 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-10-13 | 開始されました | Barclays | Underweight |
| 2025-04-28 | 開始されました | Canaccord Genuity | Buy |
| 2025-03-20 | 開始されました | Morgan Stanley | Overweight |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-10-07 | 開始されました | Citigroup | Buy |
| 2024-09-30 | 開始されました | Goldman | Neutral |
| 2024-09-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | 開始されました | Stifel | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2023-12-20 | 開始されました | TD Cowen | Outperform |
| 2023-11-10 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | 開始されました | Wells Fargo | Underweight |
| 2021-09-17 | 開始されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | SVB Leerink | Outperform |
| 2021-07-22 | 開始されました | Guggenheim | Buy |
| 2020-02-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-07 | 開始されました | Aegis Capital | Buy |
| 2016-03-08 | ダウングレード | Jefferies | Buy → Hold |
| 2016-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2016-03-07 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2016-03-01 | 開始されました | H.C. Wainwright | Buy |
| 2015-08-11 | 繰り返されました | Brean Capital | Buy |
| 2015-08-11 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-11 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-02 | 繰り返されました | WBB Securities | Strong Buy |
| 2014-11-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2013-07-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-03-08 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2013-02-26 | 繰り返されました | Oppenheimer | Outperform |
| 2013-01-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2012-10-02 | 繰り返されました | Oppenheimer | Outperform |
| 2012-09-14 | 繰り返されました | Cantor Fitzgerald | Buy |
すべてを表示
Celldex Therapeutics Inc (CLDX) 最新ニュース
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMFI Overbought - dars.gov.et
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued? - Sahm
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - marketbeat.com
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - marketbeat.com
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside - TradingView
Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock - marketbeat.com
CLDX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million - Bitget
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex: Q2 Earnings Snapshot - Barchart.com
Celldex Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M - marketscreener.com
Celldex Reports Second Quarter Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary - TradingView
Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M - Stock Titan
Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celldex reports Q2 net loss of $73.5M; cash and marketable securities $717.6M at June 30, 2026 - TradingView
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week HighTime to Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com - Investing.com South Africa
Celldex Therapeutics stock hits 52-week high at $40.30 - Investing.com
Celldex Therapeutics earnings up next as Phase III data looms - Investing.com
Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsight - The Manila Times
CLDX Q2'26 Earnings: EPS estimate is (1.06) USD - TradingView
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Biotechnology Innovator with 51% Potential Upside - DirectorsTalk Interviews
Celldex Therapeutics, Inc. $CLDX Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
29,300 Shares in Celldex Therapeutics, Inc. $CLDX Purchased by Seven Fleet Capital Management LP - marketbeat.com
CLDX Q2'26 Earnings: revenue estimate is 734.92K USD - TradingView
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - marketbeat.com
Eversept Partners LP Has $56.72 Million Stock Position in Celldex Therapeutics, Inc. $CLDX - marketbeat.com
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380 - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celldex Therapeutics Inc (CLDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celldex Therapeutics, Inc. $CLDX is Commodore Capital LP's 7th Largest Position - marketbeat.com
TradingKey - TradingKey
Celldex Therapeutics Inc (CLDX) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):